Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study - Hu, Yi; Xu, Xin; Liu, Xiao-Shun; He, Cong; Ouyang, Yao-Bin; Li, Nian-Shuang; Xie, Chuan; Peng, Chao; Zhu, Zhen-Hua; Xie, Yong; Shu, Xu; Zhu, Yin; et al. (Frontiers in immunology, 2023)
Keywords: amoxicillin; Amoxicillin - adverse effects; Anti-Bacterial Agents - adverse effects; Clarithromycin - therapeutic use; dual therapy; efficacy; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Immunology; Prospective Studies; Proton Pump Inhibitors - therapeutic use; vonoprazan; amoxicillin; Helicobacter pylori; vonoprazan; efficacy; dual therapy